Therapeutic Areas

 

Protein misfolding is the underlying cause of devastating neurodegenerative and rare diseases. Chaperone Therapeutics is developing disease-modifying therapies that directly ameliorate protein misfolding. Small molecules that elevate the activity of the protein folding machinery are in pre-clinical development. Sensitive and reliable biomarkers have been identified to monitor the efficacy of therapeutic responses.

Priority therapeutic areas under development include:

  • Huntington’s Disease and other tri-nucleotide expansion disorders

  • Amyotropic Lateral Sclerosis (Lou Gehrig’s Disease)

  • Orphan Diseases caused by protein misfolding

  • Alzheimer’s Disease

  • Parkinson’s Disease